Climb Bio CLYM 深 沪
交易中 11-12 10:42:49 美东时间
11.33
-0.920
-7.51%
华盛通- 最 高12.14
- 今 开11.97
- 成交量 20.06万股
- 最 低 11.23
- 昨 收 12.25
- 总市值 6.66亿
- 52周最高 18.33
- 市盈率 静 --
- 换手率 0.34%
- 52周最低 1.635
- 委 比 -57.14%
- 总股本 5873.82万
- 历史最高 29.69
- 量 比 0.90
- 振 幅 7.43%
- 历史最低 1.05
- 每 手 1
- 风险率 4.11%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 巴克莱维百济神州"超配"评级！目标价从415美元上调至446美元
今日重点评级关注：瑞银：维持Liberty Media"中性"评级，目标价从110美元升至1116美元；杰富瑞：维持伊诺维奥制药"买入"评级，目标价从3美元升至8美元
11-09 14:00
Wedbush Maintains Outperform on Climb Bio, Raises Price Target to $27
Wedbush analyst Laura Chico maintains Climb Bio (NASDAQ:CLYM) with a Outperform and raises the price target from $25 to $27.
11-07 00:54
Climb Bio to Present at Guggenheim 3rd Annual Healthcare Innovation Conference
Climb Bio, Inc. announced that its executive team members will participate in the Guggenheim 3rd Annual Healthcare Innovation Conference on November 9, 2026, in a Fireside Chat format. The live webcast will be available on the Climb Bio website, with a replay accessible approximately two hours post-event and archived for 30 days. Climb Bio focuses on developing disease-modifying therapies for immune-mediated diseases, including kidney conditions,...
11-02 12:00
美股大行评级 | 潜在涨幅94.81%！富瑞上调ArriVent BioPharma(AVBP)目标价至30美元，维持"买入"评级
今日重点评级关注：富瑞：维持ArriVent BioPharma"买入"评级，目标价从18美元升至30美元；古根海姆：维持第一太阳能"买入"评级，目标价从282美元升至299美元
10-28 12:30
美股大行评级 | 潜在涨幅203.03%！BTIG上调Rapport Therapeutics目标价至89美元，维持"买入"评级
今日重点评级关注：BTIG：维持Rapport Therapeutics"买入"评级，目标价从75美元升至89美元；摩根士丹利：维持希捷科技"超配"评级，目标价从1187美元升至1200美元
10-21 12:30
Deutsche Bank Initiates Coverage On Climb Bio with Buy Rating, Announces Price Target of $28
Deutsche Bank analyst David Hoang initiates coverage on Climb Bio (NASDAQ:CLYM) with a Buy rating and announces Price Target of $28.
10-21 01:54
Climb Bio To Present New Data For Its CLYM116, Budoprutug Programs Across Three Immune-Mediated Kidney Diseases At American Society Of Nephrology Kidney Week 2026
Climb Bio, Inc. (NASDAQ:CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today announced that it will present new clinical data for its CLYM116 and budoprutug programs across three immune-mediated kidney diseases at the American Societ...
10-02 21:33
Climb Bio to Present New Data at American Society of Nephrology (ASN) Kidney Week 2026 for CLYM116 and Budoprutug
Climb Bio will present new clinical data for its CLYM116 and budoprutug programs in immune-mediated kidney diseases at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver. CLYM116, targeting APRIL, shows Phase 1 safety and PK/PD results in healthy volunteers. Budoprutug, an anti-CD19 antibody, presents Phase 2 data in primary membranous nephropathy and case studies for minimal change disease. Both programs aim to address B-cell me...
10-02 13:30
Small-cap stocks with strong momentum grades and triple-digit YTD gains
A group of U.S. small-cap stocks is flashing A+ momentum grades in the latest quantitative screen, with several names posting triple-digit gains year to date. Seeking Alpha's Quant Momentum Grade meas...
09-17 21:55
美股大行评级 | 多家大行齐上调Robinhood目标价！最高看至150美元；安进股价大跌后评级遭下调
今日重点评级关注：Chardan Capital：维持Hyperion DeFi"买入"评级，目标价从7.3美元升至8.45美元；摩根大通：维持Vera Therapeutics"超配"评级，目标价从76美元升至83美元
09-09 15:36
